Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail Corporation today announced financial results for the three-month and six-month periods ended June 30, 2010.

5 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

Cornerstone Therapeutics Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency's public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

5 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Medifast net revenue for second-quarter 2010 increases 60% to $66.7 million

Medifast, Inc., a leading provider of clinically proven portion-controlled weight-loss programs, today reported financial results for the second quarter ended June 30, 2010.

5 Aug 2010

Columbia second-quarter net revenues from progesterone products increase 48% to $8.4 million

Columbia Laboratories, Inc. today announced financial results for the three- and six-month periods ended June 30, 2010.

5 Aug 2010

Alexza to raise $18.0M in registered direct offering

Alexza Pharmaceuticals, Inc. today announced that it has entered into definitive agreements with a select group of institutional investors to raise approximately $18.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants. The Company agreed to sell a total of 6,685,183 units, each unit consisting of (i) one share of common stock and (ii) one warrant to purchase 0.5 of a share of common stock, at a purchase price of $2.70 per unit.

5 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

CTI second-quarter total net operating expenses decrease to $20.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the second quarter ended June 30, 2010.

5 Aug 2010

Bionovo reports total revenue of $14,000 for second-quarter 2010

Bionovo, Inc. today announced second quarter highlights and financial results for the three months ended June 30, 2010.

5 Aug 2010

Elusys awarded second contract to develop Anthim for treatment of anthrax infection

Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Optimer second-quarter net loss decreases to $10.4 million

Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.

5 Aug 2010

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period and fiscal year ended June 30, 2010.

5 Aug 2010

AMRI second-quarter adjusted EPS increases to $0.06

AMRI today reported financial and operating results for the second quarter ended June 30, 2010.

5 Aug 2010

Anthera second-quarter total operating expenses increase to $7.9 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the second quarter ended June 30, 2010.

5 Aug 2010

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.

5 Aug 2010